STOCK TITAN

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will have its President and CEO, Michael M. Morrissey, Ph.D., present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will be webcast on www.exelixis.com, with a replay available for at least 30 days.
Positive
  • None.
Negative
  • None.

– Presentation to be webcast on www.exelixis.com

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT / 7:30 p.m. ET.

To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When will Michael M. Morrissey, Ph.D., present at the 42nd Annual J.P. Morgan Healthcare Conference?

Michael M. Morrissey, Ph.D., will present on January 8, 2024.

Where can I access the webcast of the presentation by Michael M. Morrissey, Ph.D.?

The webcast will be available on www.exelixis.com under the Event Calendar page.

Will there be a replay of the presentation available?

Yes, a replay will be available at the same location for at least 30 days.

Exelixis Inc

NASDAQ:EXEL

EXEL Rankings

EXEL Latest News

EXEL Stock Data

6.46B
255.76M
2.34%
88.14%
2.25%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
ALAMEDA

About EXEL

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.